Identification of novel brain biomarkers.
暂无分享,去创建一个
Jin-Moo Lee | Dan L Crimmins | J. Lee | J. Ladenson | V. Modur | O. Laterza | D. Crimmins | Jack H Ladenson | Y. Landt | Omar F Laterza | Vijay R Modur | Jitka V Olander | Yvonne Landt | J. Olander | Yvonne Landt
[1] W. Feinberg,et al. Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. , 1996, Stroke.
[2] M. Pelsers,et al. Detection of brain injury by fatty acid-binding proteins , 2005, Clinical chemistry and laboratory medicine.
[3] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[4] P. Coriat,et al. Influence of hemolysis on the measurement of S-100beta protein and neuron-specific enolase plasma concentrations during coronary artery bypass grafting. , 2000, Clinical chemistry.
[5] H. Lehrach,et al. Analysis of the mouse proteome. (I) Brain proteins: Separation by two‐dimensional electrophoresis and identification by mass spectrometry and genetic variation , 1999, Electrophoresis.
[6] J. Serena,et al. Plasma Metalloproteinase-9 Concentration Predicts Hemorrhagic Transformation in Acute Ischemic Stroke , 2003, Stroke.
[7] R. Anderson,et al. Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources. , 2001, The Annals of thoracic surgery.
[8] K. Blennow,et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. , 2000, Journal of Alzheimer's disease : JAD.
[9] T. Neumann-Haefelin,et al. Predicts a Malignant Course of Infarction in Patients With Acute Middle Cerebral Artery Occlusion , 2004 .
[10] L. Stead,et al. Neuron-Specific Enolase as a Marker for Acute Ischemic Stroke: A Systematic Review , 2004, Cerebrovascular Diseases.
[11] D. Laskowitz,et al. Early biomarkers of stroke. , 2003, Clinical chemistry.
[12] W. White,et al. Novel Diagnostic Test for Acute Stroke , 2003, Stroke.
[13] T. Neumann-Haefelin,et al. Serum S100B Predicts a Malignant Course of Infarction in Patients With Acute Middle Cerebral Artery Occlusion , 2004, Stroke.
[14] S. P. Fodor,et al. High density synthetic oligonucleotide arrays , 1999, Nature Genetics.
[15] H. Hårdemark,et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. , 1987, Stroke.
[16] J. Castillo,et al. New Frontiers in the Diagnosis of Ischemic Stroke , 2003 .
[17] P. Weinstein,et al. Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.
[18] S. Anant,et al. Expression of a novel regenerating gene product, Reg IV, by high density fermentation in Pichia pastoris: production, purification, and characterization. , 2003, Protein expression and purification.
[19] H. Hampel,et al. Blood‐Cerebrospinal Fluid Barrier Dysfunction for High Molecular Weight Proteins in Alzheimer Disease and Major Depression: Indication for Disease Subsets , 1997, Alzheimer disease and associated disorders.
[20] J. Arenillas,et al. Matrix Metalloproteinase Expression After Human Cardioembolic Stroke: Temporal Profile and Relation to Neurological Impairment , 2001, Stroke.
[21] D. Seligson,et al. Clinical Chemistry , 1965, Bulletin de la Societe de chimie biologique.
[22] V. Arolt,et al. S100B in brain damage and neurodegeneration , 2003, Microscopy research and technique.
[23] Gert Lubec,et al. Proteomics in brain research: potentials and limitations , 2003, Progress in Neurobiology.
[24] F. Goodwin,et al. Brain endolases as specific markers of neuronal and glial cells. , 1978, Science.
[25] D. Lockhart,et al. Expression monitoring by hybridization to high-density oligonucleotide arrays , 1996, Nature Biotechnology.
[26] Melanie Hilario,et al. Mining mass spectra for diagnosis and biomarker discovery of cerebral accidents , 2004, Proteomics.
[27] Cornford,et al. Blood-brain barrier permeability to small and large molecules. , 1999, Advanced drug delivery reviews.
[28] R. Anderson,et al. High serum S100B levels for trauma patients without head injuries. , 2001, Neurosurgery.
[29] Peter Moyer,et al. Recommendations for the Establishment of Stroke Systems of Care: Recommendations From the American Stroke Association’s Task Force on the Development of Stroke Systems , 2005, Circulation.
[30] B. G. Blijenberg,et al. Technical Performance and Diagnostic Utility of the New Elecsys® Neuron-Specific Enolase Enzyme Immunoassay , 2003, Clinical chemistry and laboratory medicine.
[31] J. Brady,et al. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction , 1998, Nature.
[32] A. Friedman,et al. Serum von Willebrand Factor, Matrix Metalloproteinase-9, and Vascular Endothelial Growth Factor Levels Predict the Onset of Cerebral Vasospasm after Aneurysmal Subarachnoid Hemorrhage , 2002, Neurosurgery.
[33] J S Alpert,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.
[34] W. Wisden,et al. Expression of the neuronal calcium sensor protein family in the rat brain , 2000, Neuroscience.
[35] Manfred Herrmann,et al. Release of Glial Tissue–Specific Proteins After Acute Stroke: A Comparative Analysis of Serum Concentrations of Protein S-100B and Glial Fibrillary Acidic Protein , 2000, Stroke.
[36] J. Vaage,et al. Biochemical markers of neurologic injury in cardiac surgery: the rise and fall of S100beta. , 2001, The Journal of thoracic and cardiovascular surgery.
[37] E. Fon,et al. Hemostatic Markers in Acute Transient Ischemic Attacks , 1994, Stroke.
[38] P. Lescuyer,et al. Identification of post‐mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration , 2004, Proteomics.
[39] S. Traynelis,et al. Serine proteases and brain damage – is there a link? , 2000, Trends in Neurosciences.